Trial Details 115 Total Sites

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).

phase

Phase 3

status

Recruiting

enrollment

950

score

60

start date

2019-05-28

last updated

2022-01-12

biomarkers

N/A

Indianapolis, Indiana
facility
Indiana University Simon Cancer Center ( Site 0075)
1 facility
Recruiting
Seattle, Washington
facility
Virginia Mason Medical Center ( Site 0028)
1 facility
Recruiting
Detroit, Michigan
facility
Henry Ford Hospital-GI/Hepatology Research ( Site 0047)
1 facility
Recruiting
Boston, Massachusetts
facility
Boston Medical Center ( Site 0025)
facility
Massachusetts General Hospital ( Site 0062)
2 facilities
Recruiting
Albuquerque, New Mexico
facility
University of New Mexico ( Site 0041)
1 facility
Recruiting
Tucson, Arizona
facility
The University of Arizona Cancer Center - North Campus ( Site 0039)
1 facility
Recruiting
Nashville, Tennessee
facility
Vanderbilt Ingram Cancer Center ( Site 0006)
1 facility
Recruiting
Cincinnati, Ohio
facility
University of Cincinnati Medical Center ( Site 0084)
1 facility
Recruiting
Gilbert, Arizona
facility
Banner MD Anderson Cancer Center ( Site 0026)
1 facility
Recruiting
Louisville, Kentucky
facility
University of Louisville ( Site 0059)
facility
James Graham Brown Cancer Center ( Site 0088)
2 facilities
Recruiting
Worcester, Massachusetts
facility
University of Massachusetts Worcester ( Site 0017)
1 facility
Recruiting
New Haven, Connecticut
facility
Smilow Cancer Hospital at Yale New Haven ( Site 0042)
1 facility
Recruiting